New Malvern Publication Shows Zetasizer APS Analyses Sticky Proteins with no Cross-Contamination
A new application note published on the Malvern Instruments website demonstrates the absence of any cross-contamination when using the company’s Zetasizer APS (Auto Plate Sampler) to analyse known ‘sticky’ proteins. The Zetasizer APS dynamic light scattering (DLS) system enables the automated measurement of multiple samples and has wide application in the rapid screening of proteins. The risk of cross-contamination is a concern to many people when considering automated analysis in a multiwell format and the experiment was designed to thoroughly test the instrument’s capabilities. The application note can be downloaded at www.malvern.com/dlsautomation.
Setup and operation of the Zetasizer APS is straightforward and its stringent cleaning protocols are designed to ensure that no cross-contamination occurs. The work described in the new application note used familiar protein samples to demonstrate the lack of detectable cross-contamination. Samples included insulin, in both “monomeric” (the insulin hexamer) and “oligomeric” forms, and Abeta, the amyloid beta peptide known for its stickiness and tendency to adhere to plastic. The Abeta sample was present in two forms, fibrillar and oligomeric.
The order in which samples were loaded onto the system was chosen so as to maximize the risk of cross-contamination. The oligomeric insulin was dispensed first using a standard pipette, followed by the small and pure insulin, and then the larger polydisperse Abeta samples. Since large protein aggregates scatter much more light than small pure protein samples, if cross-contamination were to occur the polydisperse Abeta sample would be detected within the small homogenous protein sample. The results show that after running multiple tests, there was no detectable cross-contamination.
The Zetasizer APS delivers the same high sensitivity, high specification DLS measurements as other systems in Malvern’s established Zetasizer family. The automated processing of samples in multiwell plates enables the generation of high quality DLS data with no user intervention, a major benefit in maximizing productivity. The system’s highly practical data display capability allows easy retrieval of results of interest, eliminating the need to manually scan through all measurements. In addition, the Zetasizer APS plate navigator feature acts as a data mapping tool, for rapid screening of results to retrieve the information of most interest and subsequent in-depth investigation of selected data sets.
The separate temperature controls of the plate holder and the measurement cell allow the Zetasizer APS to maintain the protein samples in optimal condition until measurement. In addition, thermal trend measurements between 2 °C to 90 °C with 0.1 °C degree precision can be defined. The plate scheduler allows the user to graphically set up size and thermal trend measurements of various samples from the same plate using a variety of different SOPs.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance